Department of Drug Development and Innovation and Department of Medical Oncology
26, rue d’Ulm
New questions are arising concerning different aspects of HER2-positive breast cancer treatment as well as new challenges, namely in the management of localized disease, from de-escalation of treatment for low-risk patients to the need for more intense therapies for patients at high risk of relapse.
These opposing strategies, however, are simply the most appropriate way to adapt treatment strategies according to the biological and clinical features of each patient.
In this article, we shed light on the most controversial aspects, namely in view of the results of clinical studies, but also concerning the legislative aspects, especially with regards to approval of the treatments mentioned.